Erin N. Kane
Known title: Chief Executive OfficerCIK: 0001684077
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
AdvanSix Featured in Chemical Stocks With Natural Gas Cost Edge. AdvanSix (ASIX) was included in a recent article highlighting three US chemical stocks that benefit from lower natural gas costs. This cost advantage is relevant to the company's production expenses in the specialty chemicals sector. The stock is currently trading below its average analyst target price, with a 52-week range extending from $14.10 to $26.73.
Transaction History
| CC | ▲ Buy | Grant | 7,182 | $0 | 5/6/2026 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 33,642 | $588K | 2/28/2026 | View on chart |
| ASIX | ▲ Buy | Grant | 111,298 | $2.0M | 2/26/2026 | View on chart |
| CC | ▲ Buy | Grant | 14,096 | $0 | 4/22/2025 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 22,213 | $616K | 2/28/2025 | View on chart |
| ASIX | ▲ Buy | Grant | 64,865 | $0 | 2/28/2025 | View on chart |
| ASIX | ▼ Sell | Open Market | 600 | $18K | 2/3/2025 | View on chart |
| ASIX | ▼ Sell | Open Market | 4,400 | $133K | 2/3/2025 | View on chart |
| ASIX | ▼ Sell | Open Market | 4,700 | $132K | 1/2/2025 | View on chart |
| ASIX | ▼ Sell | Open Market | 300 | $9K | 1/2/2025 | View on chart |
| ASIX | ▼ Sell | Open Market | 5,000 | $161K | 12/2/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 3,500 | $106K | 11/1/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 1,500 | $46K | 11/1/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 5,000 | $151K | 10/1/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 4,900 | $138K | 9/3/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 100 | $3K | 9/3/2024 | View on chart |
| CC | ▲ Buy | Grant | 8,547 | $0 | 8/6/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 3,442 | $96K | 8/2/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 1,558 | $43K | 8/1/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 8,079 | $225K | 7/31/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 6,921 | $193K | 7/30/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 3,002 | $84K | 4/4/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 613 | $17K | 4/2/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 1,385 | $39K | 4/1/2024 | View on chart |
| ASIX | ▼ Sell | Open Market | 5,000 | $142K | 3/28/2024 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 54,328 | $1.5M | 2/28/2024 | View on chart |
| ASIX | ▲ Buy | Grant | 63,962 | $0 | 2/28/2024 | View on chart |
| ASIX | ▲ Buy | Grant | 106,213 | $0 | 2/28/2024 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 13,596 | $378K | 2/24/2024 | View on chart |
| CC | ▲ Buy | Grant | 5,858 | $0 | 4/26/2023 | View on chart |
| ASIX | ▲ Buy | Grant | 187,586 | $0 | 2/28/2023 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 95,755 | $3.9M | 2/28/2023 | View on chart |
| ASIX | ▲ Buy | Grant | 6,007 | $0 | 2/28/2023 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 24,194 | $994K | 2/26/2023 | View on chart |
| CC | ▲ Buy | Grant | 4,442 | $0 | 4/27/2022 | View on chart |
| ASIX | ▲ Buy | Grant | 37,721 | $0 | 2/28/2022 | View on chart |
| ASIX | ▼ Sell | Tax Withholding | 29,415 | $1.2M | 2/28/2022 | View on chart |
| ASIX | ▲ Buy | Grant | 20,434 | $0 | 2/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.